NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Estrella Immunopharma, Inc. (ESLA) Stock Analysis

Estrella Immunopharma, Inc. (ESLA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ESLA

$0.65

+$0.01 (+0.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ESLA with… →

ESLA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.73
Previous Close
$0.64
Day's Range
0.59–0.74
52-Week Range
0.59–3.15
Volume
69.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.89
Valuation
Market Cap
$28.11M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.24
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$13.06M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.50M
1-Year Return
−40.19%
Dividend and dates
Avg Volume
36.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ESLA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−58.59%
2025+30.00%
2024+8.11%
2023−89.21%
2022+3.83%
2021 (partial year)+1.64%

As of September 4, 2026.

ESLA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$13.06M—
2024$0.00−$7.31M—
2023$0.00−$11.11M—
2022$0.00−$1.69M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$13.06M−$13.06M—
2024$0.00—−$7.31M−$7.31M—
2023$0.00—−$11.11M−$11.11M—
2022$0.00—−$1.69M−$1.69M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ESLA Valuation vs Biotechnology Median

Median of 656 stocks
MetricESLABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Estrella Immunopharma, Inc. (ESLA) is capitalised at $28.11M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The 52-week range on file runs from $0.59 to $3.15. ESLA last closed at $0.65 on September 4, 2026. That is +$0.01 (+0.78%) against the previous close. The latest close sits 10.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $13.06M. The reported profit margin is 0%. Trailing earnings per share are −0.24.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is −40.19%. Measured over 5 years, that is −41.89% a year compounded. Beta against the wider market is reported at 0.89. Daily returns over the trailing 5 years annualize to a volatility of 132.28%.

Growth & Income

The record shows no dividend for ESLA.

Across the complete calendar years on file, 2025 returned +30.00% and 2023 returned −89.21%. Of the 4 complete calendar years on file, 3 finished higher. So far in 2026 the price is −58.59%.

Peer Comparison

Estrella Immunopharma, Inc. (ESLA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Estrella Immunopharma, Inc. ESLA $28.11M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Estrella Immunopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Visit website →